Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125069273 | 12506927 | 3 | F | 20150414 | 20160720 | 20160629 | 20160729 | EXP | GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-079419 | BRISTOL MYERS SQUIBB | 44.20 | YR | F | Y | 0.00000 | 20160729 | CN | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125069273 | 12506927 | 1 | PS | ABILIFY | ARIPIPRAZOLE | 1 | Oral | 15 MG, QD | 1125 | MG | Y | 21436 | 15 | MG | QD | ||||
| 125069273 | 12506927 | 2 | SS | CLOPIXOL-ACUPHASE | ZUCLOPENTHIXOL | 1 | Intramuscular | 50 MG, UNK | Y | U | 0 | 50 | MG | INJECTION | |||||
| 125069273 | 12506927 | 3 | SS | CLOPIXOL-ACUPHASE | ZUCLOPENTHIXOL | 1 | Intramuscular | 100 MG, UNK | Y | U | 0 | 100 | MG | INJECTION | |||||
| 125069273 | 12506927 | 4 | SS | CLOPIXOL-ACUPHASE | ZUCLOPENTHIXOL | 1 | Intramuscular | 150 MG, UNK | Y | U | 0 | 150 | MG | INJECTION | |||||
| 125069273 | 12506927 | 5 | SS | CLOPIXOL-ACUPHASE | ZUCLOPENTHIXOL | 1 | Intramuscular | 100 MG, UNK | Y | U | 0 | 100 | MG | INJECTION | |||||
| 125069273 | 12506927 | 6 | SS | CLONAZEPAM. | CLONAZEPAM | 1 | Oral | 1 MG, TID | 42 | MG | U | 0 | 1 | MG | TID | ||||
| 125069273 | 12506927 | 7 | SS | OLANZAPINE. | OLANZAPINE | 1 | Oral | 1 DF, PRN | U | 0 | 1 | DF | |||||||
| 125069273 | 12506927 | 8 | SS | LORAZEPAM. | LORAZEPAM | 1 | Intramuscular | 4 MG, UNK | U | 0 | 4 | MG | INJECTION | ||||||
| 125069273 | 12506927 | 9 | SS | LORAZEPAM. | LORAZEPAM | 1 | Oral | 1 DF, PRN | U | 0 | 1 | DF | INJECTION | ||||||
| 125069273 | 12506927 | 10 | SS | LORAZEPAM. | LORAZEPAM | 1 | Intramuscular | 1 DF, PRN | U | 0 | 1 | DF | INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125069273 | 12506927 | 1 | Bipolar I disorder |
| 125069273 | 12506927 | 2 | Mania |
| 125069273 | 12506927 | 6 | Product used for unknown indication |
| 125069273 | 12506927 | 7 | Product used for unknown indication |
| 125069273 | 12506927 | 8 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125069273 | 12506927 | HO |
| 125069273 | 12506927 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125069273 | 12506927 | Medication error | |
| 125069273 | 12506927 | Neutropenia | |
| 125069273 | 12506927 | Prescribed overdose |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125069273 | 12506927 | 1 | 20150130 | 20160413 | 0 | |
| 125069273 | 12506927 | 2 | 20150331 | 20150331 | 0 | |
| 125069273 | 12506927 | 3 | 20150401 | 20150402 | 0 | |
| 125069273 | 12506927 | 4 | 20150412 | 20150412 | 0 | |
| 125069273 | 12506927 | 5 | 20150413 | 20150413 | 0 | |
| 125069273 | 12506927 | 6 | 20150329 | 20150413 | 0 | |
| 125069273 | 12506927 | 7 | 20150330 | 20150412 | 0 | |
| 125069273 | 12506927 | 8 | 20150401 | 20150402 | 0 | |
| 125069273 | 12506927 | 9 | 20150330 | 20150412 | 0 | |
| 125069273 | 12506927 | 10 | 20150330 | 20150412 | 0 |